To ensure EUPATI lives on as a successful project and a trusted brand for patient education in medicines research and development, our leadership team have agreed the continuation of EUPATI beyond the current Innovative Medicines Initiative (IMI) grant, which ends on 31 Jan 2017.
From 1 Feb 2017 EUPATI will transition to a patient-led programme within the European Patients’ Forum keeping the public-private partnership spirit, although with a leaner budget.
Over the summer EUPATI has successfully raised additional funding. We are delighted to announce that the Patient Expert Training Course will run in 2017/2018, sustaining EUPATI as an independent educational programme.
Our other core activity, the EUPATI Toolbox on Medicines R&D will continue to be provided in all available languages. Content will be updated to keep pace with external developments as necessary, for example regulatory changes. Important additional support will be given to optimise the use of the EUPATI Toolbox material through new ‘starter kits’ to enable community-run trainings, capacity building seminars for specific constituencies, and encouraging translation and uptake in other languages.
EUPATI will also continue to give support to EUPATI current and aspiring National Teams, providing coordination support, informational resources, a web platform and teleconference facilities.
These measures will ensure the EUPATI brand is maintained, and the achievements to date are exploited to the full, especially the 8-lingual EUPATI Toolbox which offers material for public information, short courses and lectures. To date, more than 49,800 unique users have used the EUPATI Toolbox in more than 69,000 sessions and have viewed more than 161,000 content pages in our seven languages. We won’t rest on our laurels however – the EUPATI team will continue to work on a long-term sustainability model to evolve EUPATI over the coming years.
As we approach the end of our first exciting phase of EUPATI, we have a sustainable initiative on state-of-the-art patient education to enable meaningful patient engagement in medicines research and development, emphasizing a truly patient-centred approach to collaboration.